Acute decline in serum sclerostin in response to PTH infusion in healthy men

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 11, 2011, Pages

  Yu, Elaine W ^a   Kumbhani, Ruchit ^a   Siwila Sackman, Erica ^a   Leder, Benjamin Z ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE; SCLEROSTIN;

ADULT; ARTICLE; BONE TURNOVER; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EXPOSURE; HORMONAL REGULATION; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

ADULT; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; CALCIUM; COLLAGEN TYPE I; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; OSTEOCALCIN; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN;

ANIMALIA;

EID: 80155124726     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1534     Document Type: Article

References (20)

1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441 (Pubitemid 32402100)
2. Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty M, Parisien MV, Lindsay R, Clemens TL, Bilezikian JP 1989 Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4:283-291 (Pubitemid 19161996)
3. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL 2005 Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583 (Pubitemid 41446595)
4. Keller H, Kneissel M 2005 SOST is a target gene for PTH in bone. Bone 37:148-158 (Pubitemid 40962421)
5. Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller H 2007 Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 22:1957-1967 (Pubitemid 351229312)
6. Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, Di Vito M, Bonucci E 2007 Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38:261-269 (Pubitemid 47106897)
7. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T 2008 Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 3:e2942
8. Rhee Y, Allen MR, Condon K, Lezcano V, Ronda AC, Galli C, Olivos N, Passeri G, O'Brien CA, Bivi N, Plotkin LI, Bellido T 2011 PTH receptor signaling in osteocytes governs periosteal bone formation and intra-cortical remodeling. J Bone Miner Res 26:1035-1046
9. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW 2004 Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814
10. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D 2005 Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887 (Pubitemid 41379516)
11. Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S 2010 Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056-5062
12. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E 11 January 2011 Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporosis Int 10.1007/s00198-010-1525-6
13. Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S 2011 The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 96:1555-1559
14. Lee H, Finkelstein JS, Miller M, Comeaux SJ, Cohen RI, Leder BZ 2006 Effects of selective testosterone and estradiol withdrawal on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 91:1069-1075 (Pubitemid 43357782)
15. van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE 2010 Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 163:833-837
16. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM 2005 Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15:928-935 (Pubitemid 40994212)
17. Joborn C, Ljunghall S, Larsson K, Lindh E, Naessén T, Wide L, AkerströmG, Rastad J 1991 Skeletal responsiveness to parathyroid hormone in healthy females: relationship to menopause and oestrogen replacement. Clin Endocrinol (Oxf) 34:335-339
18. Cosman F, Shen V, Xie F, Seibel M, Ratcliffe A, Lindsay R 1993 Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers. Ann Intern Med 118:337-343 (Pubitemid 23070617)
19. Leder BZ, Smith MR, Fallon MA, Lee ML, Finkelstein JS 2001 Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 86:511-516 (Pubitemid 32207452)
20. Mödder UI, Roforth MM, Hoey K, McCready LK, Peterson JM, Monroe DG, Oursler MJ, Khosla S 2011 Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone 49:202-207